Sino Biopharmaceutical Advances Lanifibranor and TQA2225 into Late-Stage Clinical Trials for MASH
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
NASH
Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH
Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...
Ascletis Pharma’s ASC41 Shows Promising Results in Phase II NASH Study
Ascletis Pharma Inc. (HKG: 1672), a Chinese pharmaceutical company, has announced positive interim results from...
Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...
Tasly Pharmaceuticals Gets NMPA Approval for B1344 Clinical Study in NASH
Tasly Pharmaceuticals (SHA: 600535), a China-based pharmaceutical company, has announced that it has received approval...
Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment
Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug...
United Laboratories’ UBT251 Receives Tacit Approval for NAFLD Clinical Study in China
Hong Kong firm United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category...
Novo Nordisk to Acquire Inversago Pharma in a Deal Valued Up to USD 1.1 Billion
Denmark’s leading pharmaceutical company, Novo Nordisk (NYSE: NVO), has reached an agreement to acquire Canada-based...
Eli Lilly’s Mirikizumab and Chia Tai Tianqing’s Lanifibranor Enter Breakthrough Therapy Review
US pharmaceutical major Eli Lilly’s (NYSE: LLY) mirikizumab and China-based Chia Tai Tianqing’s lanifibranor have...
Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category...
Sciwind Biosciences Leads China’s Anti-Obesity Drug Market with GLP-1 Analog Ecnoglutide
Sino-US biotech Sciwind Biosciences Co., Ltd has positioned itself as a frontrunner in China’s race...
AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...
Guangdong Zhongsheng Pharma Initiates Phase IIb Study for ZSP1601 in NASH
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the first subject enrollment in...
HighTide Therapeutics’ HTD1801 Meets Primary and Secondary Endpoints in Type 2 Diabetes Phase II Study
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced that its Phase II study for the...
Medisan Pharmaceutical Secures PPAR Agonist Technology from China Pharmaceutical University
Harbin Medisan Pharmaceutical Co., Ltd (SHE: 002900) has announced a significant patent and technology transfer...
Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment
US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its...
Inventiva and Chia Tai Tianqing’s Lanifibranor Advances with CDE Filing
France-based Inventiva S.A. and China’s Chia Tai Tianqing have successfully filed a clinical trial application...
Inventiva and Chia Tai Tianqing File Clinical Trial for Lanifibranor with CDE
France-based Inventiva S.A. and China’s Chia Tai Tianqing have filed a clinical trial application with...
Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study
US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...